A new generation of antibody variant developed by mAbsolve has been licensed to Novalgen for evaluation in their pipeline of therapeutic antibodies intended for treatment of cancer, leukaemias and cardiovascular disease. Mr Nilesh Modi, COO of Novalgen, said: I’m delighted to be working with the newly formed mAbsolve team, who individually have fantastic track records. … Read more

The STR antibody technology developed by mAbsolve for truly silenced antibodies has been licensed to ONA Therapeutics for evaluation in their pipeline of therapeutic antibodies for advanced cancer. Dr. Valerie Vanhooren, CEO of ONA Therapeutics, said: We are delighted to be working with the highly experienced mAbsolve team. Having access to the novel Fc silencing … Read more